Glioblastoma: State of the Art and Future Perspectives

Glioblastoma: State of the Art and Future Perspectives

Glioblastoma multiforme

Glioblastoma is an aggressive incurable primary tumor of the central nervous system. Median overall survival is in the range of 1.5 years even in selected clinical trials populations. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, resistance to therapy, migration and invasion, immunosuppression. With the access of novel highthroughput technologies, significant progress has been made to understand molecular and immunological signatures underlying the pathology of glioblastoma. Clinical trial designs have shifted from investigating broad “one-for-all” treatment approaches to precision oncology designs. The collection of contributions in this book aim at providing researchers and clinicians an update on different aspects of glioblastoma, i.e. progress in basic, preclinical and clinical research.

Tabatabai, Ghazaleh (editor)

Wakimoto, Hiroaki (editor)

https://directory.doabooks.org/handle/20.500.12854/68811

MDPI - Multidisciplinary Digital Publishing Institute

Publisher website
www.mdpi.com/books

2020

Sukartini

https://creativecommons.org/licenses/by/4.0/

Furnari, F.B.; Fenton, T.; Bachoo, R.M.; Mukasa, A.; Stommel, J.M.; Stegh, A.; Hahn, W.C.; Ligon, K.L.;
Louis, D.N.; Brennan, C.; et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment.
Genes Dev. 2007, 21, 2683–2710. [CrossRef] [PubMed]

Lozada-Delgado, E.L.; Grafals-Ruiz, N.; Vivas-Mejía, P.E. RNA interference for glioblastoma therapy:
Innovation ladder from the bench to clinical trials. Life Sci. 2017, 188, 26–36. [CrossRef] [PubMed]

Pdf

English

Textbooks

DOI
10.3390/books978-3-03928-261-6

ISBN
9783039282609, 9783039282616
Publisher

Basel, Switzerland